Biocryst Pharmaceuticals Inc

Research Biocryst Pharmaceuticals Inc (BCRX) on Bullrun: market cap USD 2.43B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBCRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 2.43B
• Financial periodFY2025
• RevenueUSD 874.84M
• Revenue growth94.1%
• Net incomeUSD 263.86M
• Free cash flowUSD 344.90M
• Gross margin97.8%

Valuation Snapshot

latest market cap is USD 2.43B.

About Biocryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1;

Frequently asked questions

What is Biocryst Pharmaceuticals Inc's market cap?

Biocryst Pharmaceuticals Inc's market capitalization is USD 2.43B.

What does Biocryst Pharmaceuticals Inc do?

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.